| Home | E-Submission | Sitemap | Contact Us |  
Instructions For Authors > For Authors and Reviewers > Instructions For Authors

Childhood Kidney Diseases (Child Kidney Dis) is an international, peer-reviewed biannually journal of medicine published in English. It is the official publication of The Korean Society of Pediatric Nephrology (KSPN). Child Kidney Dis covers clinical and research works relevant to all aspects of pediatric nephrology. The journal aims to serve pediatricians through the prompt publication of significant advances in pediatric nephrology and to rapidly disseminate recently updated knowledge to the public. Additionally, it will initiate dynamic, international, academic discussions concerning the major topics related to pediatric nephrology.

Manuscripts for submission to Child Kidney Dis should be prepared according to the following instructions. Child Kidney Dis follows the Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication (http://www.icmje.org), if otherwise not described below.

The Research Ethics Committee of Child Kidney Dis is organized and held immediately if any deliberation issues are found in research ethics. The Research Ethics Committee of Child Kidney Dis consists of more than five people among the editorial board members, including the editor-in-chief. The Research Ethics Committee of Child Kidney Dis holds regular meetings at least four times a year. The Committee should always monitor and guard publication ethics for all papers and be willing to publish corrections, clarifications, and retractions when needed. The Committee can decide to retract an article only when more than half of the registered members of the committee are present and more than half of them agree with the retraction. For the policies on the research and publication ethics not stated in this instructions, 쁆ood Publication Practice Guidelines for Medical Journals (http://kamje.or.kr/publishing_ethics.html, Korean Association of Medical Journal Editors), 쁆uidelines on Good Publication (http://publicationethics.org/resources/guidelines, Committee on publication ethics), 쁂ommittee on Publication Ethics, and 쁕niform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication (http://www.icmje.org, International Committee of Medical Journal Editors [ICMJE]) can be applied

1. Authorship and contributorship
An author is considered as an individual who has made substantive intellectual contributions to a published study and whose authorship continues to have important academic, social, and financial implications. The ICMJE has recommended the following criteria for authorship: 1) substantial contributions to conception and design, acquisition, analysis, and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; 3) final approval of the version to be published; and 4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. If any persons who do not meet the above four criteria, they may be placed as contributors in the Acknowledgments section.

2. Duplicate publication
Manuscripts are only accepted for publication in journals if they have not been published elsewhere. Manuscripts published in this journal should not be submitted for publication elsewhere. If the author(s) wishes to obtain a duplicate or secondary publication for various other reasons, such as for readers of a different language, he/she should obtain approval from the editors-in-chief of both the first and second journal.

3. Conflict of interest
Conflict of interest exists when an author (or the author셲 institution), reviewer, or editor has financial or personal relationships that inappropriately influence his/her actions (such relationships are also known as dual commitments, competing interests, or competing loyalties). All authors should disclose their conflicts of interest, i.e., 1) financial relationships (such as employment, consultancies, stock ownership, honoraria, paid expert testimony), 2) personal relationship, 3) academic competition, and 4) intellectual passion. These conflicts of interest must be included as a footnote on the title page or in the acknowledgement section. Each author should certify the disclosure of any conflict of interest with his/her signature. If no conflict exists, please state that 쁔he Author(s) declare(s) that there is no conflict of interest.

4. Protection of privacy, confidentiality, and written informed consent
The ICMJE has recommended the following statement for the protection of privacy, confidentiality, and written informed consent: The rights of patients should not be infringed without written informed consent. Identifying details should not be published in written descriptions, photographs, and pedigrees unless it is essential for scientific purposes and the patient (or his/her parents or guardian) provides written informed consent for publication. However, complete patient anonymity is difficult to achieve; therefore, informed consent should be obtained in the event that anonymity of the patient is not assured. For example, masking the eye region of patients in photographs is not adequate to ensure anonymity. If identifying characteristics are changed to protect anonymity, authors should provide assurance that alterations do not distort scientific meaning and editors should take note of this. When informed consent has been obtained, it should be indicated in the published article.

5. Protection of human and animal rights
While reporting experiments that involve human subjects, it should be stated that the study was performed according to the Helsinki Declaration (http://www.wma.net/en/30publications/10policies/b3/index.html) and approved by the Research Ethics Committee (REC) or the Institutional Review Board (IRB) of the institution where the experiment was performed. A written informed consent should be obtained from all subjects. In the case of an animal study, a statement should be provided indicating that the experiment process, such as the breeding and the use of laboratory animals, was approved by the REC of the institution where the experiment was performed or that it does not violate the rules of the REC of the institution or the NIH Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, http://www.nap.edu/readingroom/books/labrats/index.html). The authors should preserve raw experimental study data for at least 1 year after the publication of the paper and should present this data if required by the editorial board.

6. Registration of the clinical research
Any research that deals with clinical trial should be registered to the primary national clinical trial registration site such as http://cris.nih.go.kr/cris/index.jsp, or other sites accredited by World Health Organization or ICMJE.

7. Process for identification of and dealing with allegations of research misconduct
When the journal faces suspected cases of research and publication misconduct such as redundant (duplicate) publication, plagiarism, fraudulent or fabricated data, changes in authorship, an undisclosed conflict of interest, ethical problems with a submitted manuscript, a reviewer who has appropriated an author셲 idea or data, complaints against editors, and so on, the resolution process will follow the flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). The discussion and decision on the suspected cases are carried out by the Research Ethics Committee of the Child Kidney Dis. We will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when needed.

8. Complaints and appeals policy
The policy of Child Kidney Dis is principally intended to protect the authors, reviewers, editors, and the publisher of the journal. The process of handling complaints and appeals follows the guidelines of the Committee of Publication Ethics available from: https://publicationethics.org/appeals.

9. Data sharing policy
1) Open data policy
Child Kidney Dis does not require mandate data sharing. In the interest of transparency and in support of FAIR data principles (https://www.go-fair.org/fair-principles/), however, authors would be asked to provide the data and other artefacts supporting the results in the paper by archiving it in an appropriate public repository. Authors may provide a data availability statement, including a link to the repository they have used, in order that this statement can be published in their paper. Shared data should be cited.

2) Clinical data sharing policy
This journal follows the data sharing policy described in 쏡ata Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors (https://doi.org/10.3346/jkms.2017.32.7.1051). As of July 1, 2018 manuscripts submitted to ICMJE journals that report the results of interventional clinical trials must contain a data sharing statement as described below. Clinical trials that begin enrolling participants on or after January 1, 2019 must include a data sharing plan in the trial's registration. The ICMJE's policy regarding trial registration is explained at https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html. If the data sharing plan changes after registration this should be reflected in the statement submitted and published with the manuscript, and updated in the registry record. All of the authors of research articles that deal with interventional clinical trials must submit data sharing plan. Based on the degree of sharing plan, authors should deposit their data after deidentification and report the DOI of the data and the registered site.

All published papers become the permanent property of the Child Kidney Dis. Copyrights of all published materials are owned by the Child Kidney Dis. They also follow the Creative Commons Attribution Non-Commercial License available from: http://creativecommons.org/licenses/by-nc/3.0/. For any commercial use of material from the open access version of the journal, permission must be obtained from the Child Kidney Dis.
Every author should sign the authorship responsibility and copyright transfer agreement form, attesting that he/she fulfills the authorship criteria. Authors are required to identify their contributions to the work described in the manuscript. The manuscript, when published, will become the property of the journal.

Authors should submit manuscripts via the electronic manuscript management system (www.chikd.org) of Child Kidney Dis. Manuscripts should be submitted by the corresponding author or first author, who should indicate the address, phone & facsimile number, and e-mail address for correspondence in the title page of the manuscript. The revised manuscript should be submitted through the same web system under the same identification numbers.

Online submission process
1) Go to www.chikd.org.
2) Log in.
3) Click on 쁭ew submissions.
4) Check and confirm 쁝uthor셲 manuscript check list.
5) Upload manuscript file and copyright transfer form.
6) Your submission is completed. You will receive your registration number or return notice via email.

Failure to do so will result in return of the manuscript and possible delay in publication. Send all correspondence regarding submitted manuscripts to:
Address: 240, Gimpohangang 1-ro, Gimpo-si, Gyeonggi-do, 10078, Republic of Korea
Tel: +82-31-981-2764, Fax: +82-31-981-2765
E-mail: chikd.editor@gmail.com or ckdeditor@kspn.org

Child Kidney Dis reviews all received materials. All papers are evaluated by a double-blind, peer-review process. Manuscripts are sent to the two (or more) most relevant investigators, for reviews of the contents. The acceptance criteria for all papers are based on the quality and originality of the research and its clinical and scientific significance. An initial decision will normally be made within 3 weeks after the agreement of review by the reviewers, and the reviewers comments will then be sent to the corresponding authors. Revised manuscripts must be submitted online by the corresponding author. Failure to resubmit the revised manuscript within 4 weeks of the editorial decision is regarded as a withdrawal. The editorial office should be notified if additional time is needed or if an author chooses not to submit a revision. The editorial committee makes decisions concerning editing, revision, and acceptance or rejection, and editing may include shortening an article, reducing the number of illustrations or tables, or changing the paper's format or the order of the manuscript. The editor selects referees results of the review will be classified as follows:
  • Accepted: The manuscript will be forwarded to the publisher without further corrections.
  • Minor revisions: The author should address the comments from the reviewers, which will be confirmed by the reviewers.
  • Major revisions: The author should address the comments from the reviewers and make the appropriate corrections for review by the three reviewers.
  • Rejection: When one out of the two (or more) reviewers rejects the manuscript, the final decision is made by the editorial committee.


    All authors are required to affirm the following statements prior to their manuscript being considered:

    • 1) If the manuscript doesn't have a new result or conclusion, then it shouldn't have the same title as a previously published article.
    • 2) Once the case has been published in an original paper, it may not be reproduced as a case report. However, only in circumstances in which a novel diagnostic method, a novel therapeutic trial, or a previously unknown accompanying condition is found will the editorial board determine the possibility of acceptance.
    • 3) Clinical trials on drugs with commercial implications will be reviewed by the proper subcommittee before being reviewed for publication.
    • 4) Case reports of previously published cases will not be accepted. The editorial board will make an exception only if the case is very rare. The index of the Child Kidney Dis should be reviewed before submission of case reports.
    • 5) Rejected manuscripts may not be resubmitted.
    • 6) If the author does not address the comments made by the reviewer or if the manuscript does not follow the guidelines provided, it will be rejected.

    1. Publication type
    Child Kidney Dis publishes review articles, original articles, case reports, editorial, letters to editor, and so on.

    1) Reviews
    This type of articles offer concise reviews of important subjects in pediatric nephrology. Review articles are accepted after editorial evaluation. It should have following structures: Title page, Unstructured abstract and Keywords, Main text (Introduction, Body text, Conclusion), Conflict of interest, Acknowledgments (if necessary), References, Tables, Figures, and Legends. No more than 100 references can be cited.

    2) Original articles
    These are papers containing the results of clinical or laboratory investigations, which are sufficiently well documented to be acceptable to critical readers. The manuscript for original articles should be organized in the following order: Title page, Structured abstract and Keywords, Introduction, Materials and methods, Results, Discussion, Conflict of interest, Acknowledgments (if necessary) References, Tables, Figures, and Legends. The text should be limited to 6 tables, 6 figures, and 40 references.

    3) Case reports
    Case report should be organized in the following order: Title page, Unstructured abstract (less than 150 words) and Keywords, Introduction, Case report, Discussion, Conflict of interest, Acknowledgments (if necessary), References, Tables, Figures, and Legends. The text should be limited to 6 tables, 6 figures and 15 references.

    4) Editorial
    Editorials should be commentaries on articles published recently in the journal. Editorial topics could include active areas of research, fresh insights, and debates. The order of the submitted manuscript should include title page, discussion, conflict of interest, acknowledgments (if applicable) and references. The text should be limited to 1,500 words and 10 references. A maximum of 2 figures or tables may be included.

    5) Letters to editor
    Letters to the Editor should include brief constructive comments that concern previously published papers. Letters to the Editor should be no more two pages. It should have maximum 10 references and 2 figures or tables. Letters could be edited by the Editorial Board. Responses by the author of the subject paper may be provided in the same issue or next issue of the Journal.

    2. General guideline
    • A manuscript must be written in English. Authors (particularly non-native English speakers) who submit the original article or case report in English should check their manuscript by professional editing service prior to submission and have to submit with English editing proof.
    • The text of the manuscript, including tables and their footnotes and figure legends, must be double-spaced and in standard 12-point font on A4 size.
    • Always submit your manuscript in the MS Word format (doc or docx).
    • All pages should be numbered consecutively starting with the title page.
    • Drug and chemical names should be stated in standard chemical or generic nomenclature.
    • Units of measure should be presented according to the International System (SI) of units. All units must be preceded by one space except percentage (%) and temperature (째C).
    • Descriptions of genes or related structures in a manuscript should include the names and official symbols provided by the US National Center for Biotechnology Information (NCBI) or the HUGO Gene Nomenclature Committee.
    • Statistical expression: mean and standard deviation should be described as mean짹SD, and mean and standard error as mean짹SE. P-values should be described as P<0.05 or P=0.003.
    • Generic and brand name of medicine: for medicine, use generic names. If a brand name should be used, insert it in parentheses after the generic name.

    3. Reporting guidelines for specific study designs
    For the specific study design, such as randomized control studies, studies of diagnostic accuracy, meta-analyses, observational studies, and non-randomized studies, it is recommended that the authors follow the reporting guidelines listed in the following table.

    1. Title page
    The title page should include:
  • The concise and informative title of the article
  • The full name(s) of the author(s)
  • The institutional affiliation(s) and address(es) of the author(s)
  • The running title, of 10 words or less
  • The e-mail address, telephone and fax numbers of the corresponding author

    If several authors and institutions are listed, it should be made clear with which department and institution each author is affiliated. For a multicenter study, indicate each individual셲 affiliation using a superscript Arabic number 1,2,3.... The corresponding author or first author should be clearly designated. In a separate paragraph, an address for correspondence including the name of the corresponding author and his/her degree, address (institutional affiliation, city, zip code and country), telephone and facsimile numbers, and e-mail address should be given. The running title should not be a declarative or interrogative sentence.

    2. Abstract and Keywords
    Please provide a structured abstract of less than 250 words which should be divided into the following sections:
    • Purpose: A single sentence describing why the study was done and the type of study carried out. Clinical studies should include the setting (e.g. practice or hospital).
    • Materials and Methods: The total number of species of animals or subjects, with (where relevant) the method of selection. For in vitro studies give the cell and tissue used. Assays or assessments carried out, together with statistical tests applied.
    • Results: The main results obtained, providing means (짹 SD or SEM) or medians (with ranges) and significance levels, where necessary. Clinical data should include any withdrawals.
    • Conclusions: Implications based on the methods and results presented.
    Keywords: Authors should provide, and identify as such, up to 5 keywords or short phrases that will assist indexers in cross-indexing the article and can be published with the abstract. Use terms from the medical subject headings (MeSH) list of Index Medicus; if suitable MeSH terms are not yet available for recently introduced terms, present terms may be used. The first letter of a keyword should be capitalized (e.g., Nephrotic syndrome, Hematuria).

    Abbreviations, if needed, should be kept to an absolute minimum, and given with proper identifications. Abstracts for case reports and review articles provide within one paragraph the purpose, methods, important results, and derived conclusion of the study in an unstructured format, but carry the same word count restrictions.

    3. Manuscript
    1) Introduction
    General enough references to the most pertinent papers, to inform readers; and others relevant findings are described here. It also includes the specific question driving the authors particular investigation.

    2) Materials and methods
    We endorse the principles embodied in the Declaration of Helsinki and expect that all investigations involving human materials have been performed in accordance with these principles. Animal experiments must be reviewed and approved by an appropriate committee (Institutional Animal Care and Use Committee) for the care and use of animals. Studies involving pathogens requiring a high degree of biosafety should pass the review of a relevant Institutional Biosafety Committee. The approval of the experimental protocol should be described in the Methods section. An explanation of the experimental methods should be concise and sufficient for repetition by other qualified investigators. Procedures that have been published previously should not be described in detail; however, new or significant modifications of previously published procedures need full descriptions. The sources of special chemicals or preparations should be given (i.e., name of company, city and state, and country). Methods of statistical analyses and criteria of significance level should be described. In case reports, case histories, or case descriptions, replace the Materials and methods section as well as the Results section.

    3) Results
    This part should be presented logically using text, tables, and illustrations. Excessive textual repetition of table or figure contents should be avoided.

    4) Discussion
    The data should be interpreted concisely without repeating materials already presented in the Results section. Speculation is permitted, but it must be supported by the authors presented data and be well-founded.

    5) Acknowledgments
    All persons who have made substantial contributions, but who are not eligible as authors, are named in the acknowledgments section. If the type of paper is case report, the corresponding author should include 쐏atient consent with IRB number additionally.

    For example:
       >Patient consent: This study was approved by the institutional review board (IRB), and the consent was waived due to the nature of the retrospective study (IRB number XX). (case report)

    6) Conflict of interest: The corresponding author of an article is asked to inform the editor of the authors' potential conflicts of interest possibly influencing their interpretation of data. A potential conflict of interest should be disclosed in the manuscript even when the authors are confident that their judgments have not been influenced in preparing the manuscript. Such conflicts may be financial support or private connections to pharmaceutical companies, political pressure from interest groups, or academic problems (e.g., employment/ affiliation, grants or funding, consultancies, stockownership or options, royalties, or patents filed, received, or pending). Information concerning support should be given in this section. The corresponding author will include a summary statement in the text of the manuscript in a separate section before the reference list, that reflects what is recorded in the potential conflict of interest disclosure form (s).

    See below examples of disclosures:
       >Funding: This study was funded by X (grant number X).
       >Conflict of Interest: Author A has received research grants from Company A. Author B has received a speaker honorarium from Company X and owns stock in Company Y. Author C is a member of committee Z.

    If no conflict exists, the authors should state:
       >Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
       >Conflict of Interest: The authors declare that they have no conflict of interest.

    7) ORCID (Open Research and Contributor ID)
    The ORCID iDs of all authors should be provided prior to the reference section. One could register for the ORCID iD at <https://orcid.org/register>.

    Examples of ORCID iDs
    Gil Dong Hong https://orcid.org/0000-0001-1234-4321
    Chul Su Kim https://orcid.org/0000-0002-3456-1002

    8) References
    References should be numbered consecutively in the order in which they are first mentioned in the main text. Each reference should be cited as superscript Arabic number 1), 1, 2), or 1-3), at the end of the related sentence in the text. Reference citations in the main text should be made with consecutive numbers in parenthesis (Vancouver style). In the Reference section, they should be listed in the order of citation within the main text, together with the corresponding number.
    • Authors are responsible for the accuracy and completeness of their references and correct text citations.
    • Papers in press may be listed among the references with the journal name and tentative year of publication.
    • Unpublished data or personal communications can be listed only with the author's written permission.
    • Other types of references not described below should follow The NLM Style Guide for Authors, Editors, and Publishers (http://www.nlm.nih.gov/citingmedicine).

    Examples of reference style

    Journal article
    Choe JY, Jang KM, Hwang YJ, Choi BS, Park JK, Yoon YR, et al. Effects of age and sex on the pharmacokinetics of tacrolimus during pediatric kidney transplantation: A single center study. Child Kidney Dis 2014;18:18-23.

    Book & Book chapter
    Volpe JJ. Neurology of the newborn. 5th ed. Philadelphia: Saunders/Elsevier, 2008.
    Hong CE. Textbook of pediatrics. 9th ed. Seoul: Korea Textbook Publishing Co., 2008.
    Pan ES, Cole FS, Weinttrub PS. Viral infections of the fetus and newborn. In: Taeusch HW, Ballard RA, Gleason CA, editors. Avery셲 diseases of the newborn. 8th ed. Philadelphia: Elsevier Saunders, 2005:495-529.

    International Committee of Medical Journal Editor. Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication [Internet]. Philadelphia: International Committee of Medical Journal Editor; c2009 [cited 2012 Nov 1]. Available from: http://www.icmje.org/urm_main.html.

    4. Table(s)
    Tables should be typed double-spaced on separate pages within manuscript, and they should be titled and numbered in Arabic numerals in the order of their first citation in the text. Each column should be given a short heading. Only the first letter of the first word in each row and column should be capital letters. If numerical measurements are given, the unit of measurement should be included in the each heading. The statistical significance of observed differences in the data should be indicated by the appropriate statistical analysis. All abbreviations should be defined in footnotes. For special remarks, superscripts *, , , 짠, 닪, 쨋, **, 졻, △... should be used. No more than 6 tables are needed.

    5. Figure(s)
    The author is responsible for submitting prints that are of sufficient quality to permit accurate reproduction, and for approving the final color galley proof. All photographs should be correctly exposed and sharply focused. The entire expense of reproducing color photographs will be charged to the author; current estimates for color reproduction can be obtained from the Editorial Office. Child Kidney Dis assumes no responsibility for the quality of the photography as it appears in the Journal. Symbols, arrows, or letters used in photographs should contrast with the background. A legend for each light microscopic photograph should include name of stain and magnification (i.e., H&E, 횞400); electron microscopic photography should have an internal scale marker. All kinds of figures may be reduced, enlarged, or trimmed for publication by the editor. No more than 6 figures are needed. All the legends for figures should be double-spaced. Do not use a separate sheet for each legend. Figure legends should describe briefly the data shown, explain any abbreviations or reference points in the photograph. The figures should be numbered in the form Fig. 1, Fig. 2, and Fig. 3. Related figures should be combined into one figure, with each subfigure denoted by the letters, A, B, C, and so on, following the Arabic number of the main figure (i.e., Fig. 1A; Fig. 1B, C; Fig. 1A-C). Figures should be submitted as Tiff or EPS file format. If the only possible file format is JPEG, it must be in highest quality with minimum compression. It is recommended to size original figure widths to 4 inches wide. The minimum requirements for digital resolution are:
    -900 DPI/PPI for black and white images, such as line drawings or graphs.
    -300 DPI/PPI for picture-only photographs.
    -600 DPI/PPI for photographs containing pictures and line elements, i.e., text labels, thin lines, arrows.

    1. Final version upload
    When accepted for publication, the authors institutional affiliations should be inserted into the text of the final revised manuscript and uploaded to the online submission system. Files containing figures must be named according to the figure number (ex: Fig. 1. jpg).

    2. Galley proof
    After corrections have been made, an accepted manuscript will be sent to the publisher for printing. The proof may be revised more than once by the corresponding author, if needed. The author should double-check for corrections in the content, title, affiliation, capitalization, locations of figures, and references. Corresponding authors are responsible for further corrections made after printing.

    3. Article processing charge
    There is no submission fee or page charge. Article processing charge can be applied for accepted articles, according to the number of tables or figures (approximately $20~$50). A minimum of 50 offprints will be provided upon request (after payment). Reprints are available at any time after publication; however, reprints ordered after publication may be subject to increases in price.

    4. Confirmation of acceptance
    Once the manuscript is at the publisher, confirmation of acceptance by the Child Kidney Dis may be issued. Registering for the board exams, a receipt of confirmation may be ordered for the accepted manuscript.

    5. Post-publication discussions
    The postpublication discussion is available through letter to the editor. If any readers have a concern on any articles published, they can submit letter to the editor on the articles. If there founds any errors or mistakes in the article, it can be corrected through errata, corrigenda, or retraction.

    • 뼞 A covering letter stating the material has not been published previously, and will not be submitted for publication elsewhere, and stating conflicts of interest of all listed authors, if any.
    • 뼞 Each author has read the manuscript and agrees with this submission.
    • 뼞 Copyright transform has been signed by all authors.
    • 뼞 Written permission from publishers to reproduce or adapt previously published illustrations or tables included.
    • 뼞 Informed consent forms for identifiable patient descriptions, photographs and pedigrees are included.
    • 뼞 The statement for IRB approval (with IRB number) must be provided.
    • 뼞 Authors must disclose any potential conflict of interest including any financial, personal or other relationships.
    • 뼞 The English Editing Certificate must be submitted for the authors whose native language is not English.
    • 뼞 The ORCID iDs of all authors should be provided prior to the reference section .
    • 뼞 The manuscript must be written by MS Word, typing with 12-point font and double-space on A4 size.
    • 뼞 Sequence of title page, abstract and keywords, introduction, materials and methods, results, discussion, acknowledgments (patient consent), funding/ conflicts of interest, ORCID iD , references, tables and figure legends. All pages should be numbered consecutively starting with the title page.
    • 뼞 Title page with article title, authors full name(s) and affiliation, address for correspondence (including telephone and fax numbers and e-mail address), running title (less than 10 words), and footnotes, if any.
    • 뼞 Abstract in structured format for original article and in unstructured format for review articles and case reports (maximum of 250 words), and keywords as in MeSH.
    • 뼞 Generic names are used for all drugs. Trade names are avoided.
    • 뼞 Research or project support/funding is noted in acknowledgments section.
    • 뼞 References listed in a proper format. Check that all references listed in the references section are cited in the text and vice versa.
        - No more than 100 references are cited in review article.
        - No more than 40 references are cited in original article.
        - No more than 15 references are cited in case report.
    • 뼞 All table and figure numbers are found in the text.
    • 뼞 No more than 6 table and 6 figures are inserted
    • 뼞 Include a title for each table and figure (a brief phrase no longer than 10 to 15 words) and explanatory legend as needed.
    Author's Index
    Author's Index
    Manuscript Submission
    To submit a manuscript, please visit the Child Kidney Dis e-submission management system at esubmit, read the Instructions for Authors, and log into the Child Kidney Dis e-submission system. For assistance with manuscript submission, please contact: ckdeditor@kspn.org.
    Free archive
    Anyone may access any past or current articles without logging in.
    Editorial Office
    240, Gimpohangang 1-ro, Gimpo-si, Gyeonggi-do, 10078, Republic of Korea
    TEL : +82-31-981-2764   FAX : +82-31-981-2765   E-mail : chikd.editor@gmail.com or ckdeditor@kspn.org

    Copyright© Korean Society of Pediatric Nephrology.                 Developed in M2PI
    About |  Browse Articles |  Current Issue |  For Authors and Reviewers